{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:30:01Z","timestamp":1787239801830,"version":"build-2736575974"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejphar.2025.178312","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:55:35Z","timestamp":1761897335000},"page":"178312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Potential role of Aliskiren in cancer modulation compared to other Renin-Angiotensin inhibitors: an in-depth review"],"prefix":"10.1016","volume":"1008","author":[{"given":"Ananya","family":"De","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Calcutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Panella","family":"Della Pietra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Loffredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Vigilante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafiah","family":"Izhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Pesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-9416","authenticated-orcid":false,"given":"Mariadelina","family":"Simeoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178312_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cmpb.2017.10.014","article-title":"DIETOS: a dietary recommender system for chronic diseases monitoring and management","volume":"153","author":"Agapito","year":"2018","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.ejphar.2025.178312_bib2","article-title":"Conditional deletion of smooth muscle Cullin-3 causes severe progressive hypertension","volume":"5","author":"Agbor","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2025.178312_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/HYPERTENSIONAHA.121.18192","article-title":"Hypertension pharmacological treatment in adults: a world health organization guideline executive summary","volume":"79","author":"Al-Makki","year":"2022","journal-title":"Hypertension (Dallas, Tex. : 1979"},{"key":"10.1016\/j.ejphar.2025.178312_bib4","first-page":"809","article-title":"Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension","volume":"3","author":"Allikmets","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejphar.2025.178312_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11605-007-0403-9","article-title":"Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1\/2 signaling","volume":"12","author":"Anandanadesan","year":"2008","journal-title":"J. Gastrointest. Surg. : official journal of the Society for Surgery of the Alimentary Tract"},{"key":"10.1016\/j.ejphar.2025.178312_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","article-title":"Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial","volume":"26","author":"Andersen","year":"2008","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2025.178312_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2174\/1389450115666140211113040","article-title":"Efficacy and safety profile of aliskiren: practical implications for clinicians","volume":"9","author":"Angeli","year":"2014","journal-title":"Curr. Drug Saf."},{"issue":"389","key":"10.1016\/j.ejphar.2025.178312_bib8","first-page":"e381","article-title":"Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice","volume":"33","author":"Ara\u00fajo","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejphar.2025.178312_bib9","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejphar.2025.178312_bib10","doi-asserted-by":"crossref","first-page":"55437","DOI":"10.18632\/oncotarget.10583","article-title":"Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis","volume":"7","author":"Arundhathi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178312_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117181","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: a meta-analysis","volume":"242","author":"Asgharzadeh","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2025.178312_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.mnh.0000242176.36953.f7","article-title":"Renin inhibition","volume":"15","author":"Azizi","year":"2006","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejphar.2025.178312_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310637","article-title":"An in silico molecular docking and simulation study to identify potential anticancer phytochemicals targeting the RAS signaling pathway","volume":"19","author":"Azmal","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178312_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2025.178312_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152510790796174","article-title":"Aliskiren: a new drug for an old problem","volume":"8","author":"Barrios","year":"2010","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178312_bib16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/ijms25020846","article-title":"Aliskiren-loaded nanoparticles downregulate (pro)renin receptor and ACE gene expression in the heart of spontaneously hypertensive rats: effect on NADPH oxidase","volume":"25","author":"Barta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178312_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025714","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: a systematic review and meta-analysis","volume":"100","author":"Batais","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2025.178312_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMra2300923","article-title":"Tumor lysis syndrome","volume":"393","author":"Bociek","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178312_bib19","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/pros.20980","article-title":"Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor","volume":"69","author":"Bose","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2025.178312_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","article-title":"Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial","volume":"377","author":"Brown","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2025.178312_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174153","article-title":"ERK1,2 signalling pathway along the nephron and its role in acid-base and electrolytes balance","volume":"20","author":"Capolongo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178312_bib22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (Angiotensin-Converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension (Dallas, Tex. : 1979"},{"key":"10.1016\/j.ejphar.2025.178312_bib23","doi-asserted-by":"crossref","first-page":"E931","DOI":"10.1503\/cmaj.240003","article-title":"Renin-angiotensin system inhibitors and risk of hepatocellular carcinoma among patients with hepatitis B virus infection","volume":"196","author":"Chen","year":"2024","journal-title":"CMAJ (Can. Med. Assoc. J.) : Canadian Medical Association journal = journal de l'Association medicale canadienne"},{"key":"10.1016\/j.ejphar.2025.178312_bib24","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension (Dallas, Tex. : 1979"},{"key":"10.1016\/j.ejphar.2025.178312_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40620-015-0256-3","article-title":"How to improve duration and efficiency of the antiproteinuric response to ramipril: RamiPROT-a prospective cohort study","volume":"30","author":"Cianfrone","year":"2017","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2025.178312_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143539","article-title":"Involvement of the substance P\/Neurokinin-1 receptor system in cancer","volume":"14","author":"Cove\u00f1as","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178312_bib27","author":"Cove\u00f1as","year":"2024"},{"key":"10.1016\/j.ejphar.2025.178312_bib28","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/aje\/kwz106","article-title":"Use of antihypertensive medications and survival rates for breast, colorectal, lung, or stomach cancer","volume":"188","author":"Cui","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ejphar.2025.178312_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034901","article-title":"The association between angiotensin receptor blockers and lung, bladder, and Colon cancer development: a 10-year multicentric retrospective Lebanese study","volume":"102","author":"Dagher","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2025.178312_bib30","first-page":"1245","article-title":"Angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis","volume":"26","author":"Dai","year":"2015","journal-title":"Cancer Causes Control : CCC"},{"key":"10.1016\/j.ejphar.2025.178312_bib31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2025.178312_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.31557\/APJCP.2020.21.2.325","article-title":"The effect of ACE inhibitor on the quality of life amongst patients with cancer cachexia","volume":"21","author":"Dehghani","year":"2020","journal-title":"Asian Pac. J. Cancer Prev. APJCP : Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ejphar.2025.178312_bib33","first-page":"12","article-title":"Effects of antihypertensive drugs use on risk and prognosis of colorectal cancer: a meta-analysis of 37 observational studies","author":"Deng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178312_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","article-title":"Angiotensin receptors: a new role in cancer?","volume":"16","author":"Deshayes","year":"2005","journal-title":"Trends Endocrinol. Metabol.: TEM (Trends Endocrinol. Metab.)"},{"key":"10.1016\/j.ejphar.2025.178312_bib35","doi-asserted-by":"crossref","first-page":"169s","DOI":"10.1378\/chest.129.1_suppl.169S","article-title":"Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines","volume":"129","author":"Dicpinigaitis","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2025.178312_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/circ.118.suppl_18.S_886-c","article-title":"Abstract 4423: the AGELESS study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients \u2265 65 years of age with systolic hypertension","volume":"118","author":"Duprez","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178312_bib37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin. Nutr. (Edinb.)"},{"key":"10.1016\/j.ejphar.2025.178312_bib38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.biopha.2016.07.039","article-title":"Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R\/VEGF pathway","volume":"83","author":"Fan","year":"2016","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.ejphar.2025.178312_bib39","doi-asserted-by":"crossref","first-page":"10562","DOI":"10.4238\/2014.December.12.19","article-title":"Hypoxia induces dysregulation of local renin-angiotensin system in mouse lewis lung carcinoma cells","volume":"13","author":"Fan","year":"2014","journal-title":"Genet. Mol. Res. : GMR"},{"key":"10.1016\/j.ejphar.2025.178312_bib40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2025.178312_bib41","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1096\/fj.15-275552","article-title":"Aldosterone mediates metastatic spread of renal cancer via the G protein-coupled estrogen receptor (GPER)","volume":"30","author":"Feldman","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2025.178312_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1753944709353426","article-title":"Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart","volume":"4","author":"Ferreira","year":"2010","journal-title":"Therapeutic advances in cardiovascular disease"},{"key":"10.1016\/j.ejphar.2025.178312_bib43","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1681\/ASN.2004100874","article-title":"Renin inhibition: what are the therapeutic opportunities?","volume":"16","author":"Fisher","year":"2005","journal-title":"J. Am. Soc. Nephrol. : JASN"},{"key":"10.1016\/j.ejphar.2025.178312_bib44","article-title":"[Hyponatremia and Electrolyte Disorders in Cancer Patients]","author":"Florio","year":"2023","journal-title":"G. Ital. Nefrol.\u202f: organo ufficiale della Societa italiana di nefrologia, 40 (Suppl 81), 2023-S81"},{"key":"10.1016\/j.ejphar.2025.178312_bib45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1159\/000540908","article-title":"Acute kidney disease in oncology: a new concept to enhance the understanding of the impact of kidney injury in patients with cancer","volume":"49","author":"Floris","year":"2024","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.ejphar.2025.178312_bib46","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.3390\/ijerph19084862","article-title":"Cancers: what are the costs in relation to disability-adjusted life years? A systematic review and meta-analysis","volume":"19","author":"Garlasco","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.ejphar.2025.178312_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11010-008-9884-4","article-title":"Angiotensin metabolites can stimulate receptors of the Mas-related genes family","volume":"319","author":"Gembardt","year":"2008","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.178312_bib48","first-page":"124","article-title":"The kinin system--bradykinin: biological effects and clinical implications. Multiple role of the kinin system--bradykinin","volume":"11","author":"Golias","year":"2007","journal-title":"Hippokratia"},{"key":"10.1016\/j.ejphar.2025.178312_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252211945","article-title":"Metabolic, inflammatory, and molecular impact of cancer cachexia on the liver","volume":"25","author":"Gon\u00e7alves","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178312_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010123","article-title":"Hypertension: a continuing public healthcare issue","volume":"26","author":"Goorani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2025.178312_bib51","first-page":"S22","article-title":"The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension","volume":"8","author":"Gradman","year":"2007","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.178312_bib52","doi-asserted-by":"crossref","first-page":"H736","DOI":"10.1152\/ajpheart.00937.2006","article-title":"Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)","volume":"292","author":"Grobe","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2025.178312_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/hr.2009.184","article-title":"Reinventing the ACE inhibitors: some old and new implications of ACE inhibition","volume":"33","author":"Hanif","year":"2010","journal-title":"Hypertens. Res. : official journal of the Japanese Society of Hypertension"},{"key":"10.1016\/j.ejphar.2025.178312_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12935-023-03080-9","article-title":"The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies","volume":"23","author":"Hassani","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2025.178312_bib55","first-page":"4089","article-title":"Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies","volume":"20","author":"Haznedaroglu","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.178312_bib56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.14423\/SMJ.0000000000001293","article-title":"Association between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and lung cancer","volume":"114","author":"Helgeson","year":"2021","journal-title":"South. Med. J."},{"key":"10.1016\/j.ejphar.2025.178312_bib57","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.ejphar.2025.178312_bib58","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/bjc.1998.145","article-title":"Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma","volume":"77","author":"Hii","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178312_bib59","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ymgme.2012.06.015","article-title":"Acid sphingomyelinase (asm) deficiency patients in the Netherlands and Belgium: disease spectrum and natural course in attenuated patients","volume":"107","author":"Hollak","year":"2012","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejphar.2025.178312_bib60","first-page":"9182","article-title":"KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro","volume":"8","author":"Hu","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ejphar.2025.178312_bib61","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/jch.14695","article-title":"Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: a systematic review, and network meta-analysis","volume":"25","author":"Hu","year":"2023","journal-title":"Journal of clinical hypertension (Greenwich, Conn.)"},{"key":"10.1016\/j.ejphar.2025.178312_bib62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.ki.5002243","article-title":"Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells","volume":"72","author":"Huang","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2025.178312_bib63","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","article-title":"Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy","volume":"6","author":"Incio","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejphar.2025.178312_bib64","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1254\/jjp.87.318","article-title":"A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors","volume":"87","author":"Ishihara","year":"2001","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178312_bib65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bcp.2018.03.008","article-title":"The role of angiotensin II in cancer metastasis: potential of renin-angiotensin system blockade as a treatment for cancer metastasis","volume":"151","author":"Ishikane","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178312_bib66","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.cellsig.2012.04.003","article-title":"How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?","volume":"24","author":"Jagadeesh","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejphar.2025.178312_bib67","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1470320313491997","article-title":"In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme","volume":"16","author":"Joseph","year":"2015","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS : JRAAS"},{"key":"10.1016\/j.ejphar.2025.178312_bib68","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jch.14187","article-title":"Effect of angiotensin receptor blockers on the development of cancer: a nationwide cohort study in Korea","volume":"23","author":"Jung","year":"2021","journal-title":"Journal of clinical hypertension (Greenwich, Conn.)"},{"key":"10.1016\/j.ejphar.2025.178312_bib69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/08037050310001057","article-title":"Angiotensin AT1\/AT2 receptors: regulation, signalling and function","volume":"12","author":"Kaschina","year":"2003","journal-title":"Blood Press."},{"key":"10.1016\/j.ejphar.2025.178312_bib71","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1369\/00221554211026295","article-title":"The role of the renin-angiotensin system in the cancer stem cell niche","volume":"69","author":"Kilmister","year":"2021","journal-title":"J. Histochem. Cytochem. : official journal of the Histochemistry Society"},{"key":"10.1016\/j.ejphar.2025.178312_bib72","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41371-023-00825-x","article-title":"Preexisting hypertension and cancer therapy: evidence, pathophysiology, and management recommendation","volume":"37","author":"Koskina","year":"2023","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejphar.2025.178312_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-0774.2007.00025.x","article-title":"Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer","volume":"20","author":"Kosugi","year":"2007","journal-title":"Hum. Cell"},{"key":"10.1016\/j.ejphar.2025.178312_bib74","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3171\/2016.9.JNS16431","article-title":"Pro)renin receptor is crucial for glioma development via the Wnt\/\u03b2-catenin signaling pathway","volume":"127","author":"Kouchi","year":"2017","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ejphar.2025.178312_bib75","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006687","article-title":"Use of ACE (Angiotensin-Converting enzyme) inhibitors and risk of lung cancer: a nationwide nested case-control study","volume":"14","author":"Kristensen","year":"2021","journal-title":"Circulation. Cardiovascular quality and outcomes"},{"key":"10.1016\/j.ejphar.2025.178312_bib76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00424-012-1105-z","article-title":"The (Pro)renin receptor. A decade of research: what have we learned?","volume":"465","author":"Krop","year":"2013","journal-title":"Pflueg. Arch. Eur. J. Physiol."},{"key":"10.1016\/j.ejphar.2025.178312_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071767","article-title":"Renin-angiotensin-aldosterone system and immunomodulation: a state-of-the-art review","volume":"10","author":"Laghlam","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178312_bib78","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","article-title":"Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system","volume":"144","author":"Lavoie","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.178312_bib79","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00005344-199711000-00019","article-title":"Angiotensin-(1-7) and the rat aorta: modulation by the endothelium","volume":"30","author":"le Tran","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178312_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030747","article-title":"Association between angiotensin-converting enzyme inhibitors and lung Cancer-A nationwide, population-based, propensity score-matched cohort study","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178312_bib81","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/ddr.21597","article-title":"Angiotensin II-induced micro RNA-21 culprit for non-small-cell lung adenocarcinoma","volume":"80","author":"Luan","year":"2019","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejphar.2025.178312_bib82","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.ki.5002732","article-title":"Antihypertensive therapy with aliskiren","volume":"73","author":"Luft","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2025.178312_bib83","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0162-3109(99)00104-6","article-title":"Kallikrein-kinin in infection and cancer","volume":"43","author":"Maeda","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ejphar.2025.178312_bib84","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.18632\/oncotarget.6837","article-title":"Is angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy protective against prostate cancer?","volume":"7","author":"Mao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178312_bib85","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.3390\/cancers15235590","article-title":"Cancer cachexia: new insights and future directions","volume":"15","author":"Mariean","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178312_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f3730","article-title":"FDA officials disagree on safety of angiotensin receptor blockers","volume":"346","author":"McCarthy","year":"2013","journal-title":"BMJ : British Medical Journal"},{"key":"10.1016\/j.ejphar.2025.178312_bib87","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/ajh\/hpz146","article-title":"Angiotensin-(1-7): Translational avenues in cardiovascular control","volume":"32","author":"Medina","year":"2019","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2025.178312_bib88","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.108.184911","article-title":"Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart","volume":"103","author":"Mercure","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178312_bib89","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00726-014-1736-9","article-title":"Involvement of substance P and the NK-1 receptor in human pathology","volume":"46","author":"Mu\u00f1oz","year":"2014","journal-title":"Amino Acids"},{"key":"10.1016\/j.ejphar.2025.178312_bib90","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.arbres.2023.09.017","article-title":"Long-term use of angiotensin-converting enzyme inhibitors increases substance P levels, which is involved in the risk of lung cancer","volume":"59","author":"Mu\u00f1oz","year":"2023","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.ejphar.2025.178312_bib91","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.critrevonc.2014.10.014","article-title":"Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach","volume":"94","author":"Muscaritoli","year":"2015","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.ejphar.2025.178312_bib92","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jash.2008.04.012","article-title":"Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1-7)3292 rats","volume":"2","author":"Nadu","year":"2008","journal-title":"Journal of the American Society of Hypertension : JASH"},{"key":"10.1016\/j.ejphar.2025.178312_bib93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-030-50224-9_7","article-title":"Renin-angiotensin system in the tumor microenvironment","volume":"1277","author":"Nakamura","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2025.178312_bib94","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/cas.13423","article-title":"Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment","volume":"109","author":"Nakamura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2025.178312_bib95","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11906-013-0416-6","article-title":"AT(2) receptor and tissue injury: therapeutic implications","volume":"16","author":"Namsolleck","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejphar.2025.178312_bib97","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2009030300","article-title":"The biology of the (Pro)renin receptor","volume":"21","author":"Nguyen","year":"2010","journal-title":"J. Am. Soc. Nephrol. : JASN"},{"key":"10.1016\/j.ejphar.2025.178312_bib98","doi-asserted-by":"crossref","first-page":"62545","DOI":"10.18632\/oncotarget.19117","article-title":"Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies","volume":"8","author":"Ni","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178312_bib99","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","article-title":"Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker","volume":"49","author":"O'Brien","year":"2007","journal-title":"Hypertension (Dallas, Tex. : 1979"},{"key":"10.1016\/j.ejphar.2025.178312_bib100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jcp.20061","article-title":"The role of substance P in inflammatory disease","volume":"201","author":"O'Connor","year":"2004","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2025.178312_bib102","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2220\/biomedres.35.117","article-title":"Expression of (Pro)renin receptor in breast cancers and its effect on cancercell proliferation","volume":"35","author":"Ohba","year":"2014","journal-title":"Biomedical research (Tokyo, Japan)"},{"key":"10.1016\/j.ejphar.2025.178312_bib103","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2014.09.019","article-title":"The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer","volume":"355","author":"Okazaki","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178312_bib104","article-title":"Exploring the impact of ACE inhibition in immunity and disease","volume":"2022","author":"Oosthuizen","year":"2022","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS : JRAAS"},{"key":"10.1016\/j.ejphar.2025.178312_bib105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2025.178312_bib106","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","article-title":"Management of hypertension in patients with cancer: challenges and considerations","volume":"16","author":"Pandey","year":"2023","journal-title":"Clinical Kidney Journal"},{"key":"10.1016\/j.ejphar.2025.178312_bib107","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design","author":"Parving","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2025.178312_bib108","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/CS20120461","article-title":"Angiotensin-(1-7): beyond the cardio-renal actions","volume":"124","author":"Passos-Silva","year":"2013","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2025.178312_bib109","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.biopha.2018.03.157","article-title":"Aliskiren: preclinical evidence for the treatment of hyperproliferative skin disorders","volume":"104","author":"Pawloski","year":"2018","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.ejphar.2025.178312_bib110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/1535-7163.MCT-14-0981","article-title":"Angiotensin-(1-7) decreases cell growth and angiogenesis of human nasopharyngeal carcinoma xenografts","volume":"15","author":"Pei","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178312_bib111","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2025.178312_bib113","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ijc.30062","article-title":"Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis","volume":"139","author":"Raimondi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178312_bib114","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1007\/s11033-022-07539-2","article-title":"A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases","volume":"49","author":"Rex","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2025.178312_bib115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2018.03.017","article-title":"Bradykinin in asthma: modulation of airway inflammation and remodelling","volume":"827","author":"Ricciardolo","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178312_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23095281","article-title":"Captopril, a renin-angiotensin system inhibitor, attenuates tumour progression in the regenerating liver following partial hepatectomy","volume":"23","author":"Riddiough","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178312_bib117","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.21873\/anticanres.13639","article-title":"Renin-angiotensin inhibition in combating malignancy: a review","volume":"39","author":"Rosenthal","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2025.178312_bib118","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2013.03.048","article-title":"Bradykinin-induced asthmatic fibroblast\/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways","volume":"710","author":"Sabatini","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178312_bib119","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1161\/HYPERTENSIONAHA.110.149815","article-title":"Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling","volume":"55","author":"Santiago","year":"2010","journal-title":"Hypertension (Dallas, Tex. : 1979"},{"key":"10.1016\/j.ejphar.2025.178312_bib120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1152\/physiolgenomics.00227.2003","article-title":"Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats","volume":"17","author":"Santos","year":"2004","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.ejphar.2025.178312_bib121","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.HYP.0000052947.60363.24","article-title":"Characterization of a new selective antagonist for angiotensin-(1-7), D-pro7-angiotensin-(1-7)","volume":"41","author":"Santos","year":"2003","journal-title":"Hypertension (Dallas, Tex. : 1979"},{"key":"10.1016\/j.ejphar.2025.178312_bib122","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejphar.2025.178312_bib124","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178312_bib125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jcb.22031","article-title":"Effect of tamoxifen and retinoic acid on bradykinin induced proliferation in MCF-7 cells","volume":"106","author":"Searovic","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.178312_bib126","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1113\/jphysiol.2003.051326","article-title":"Substance P presynaptically depresses the transmission of sensory input to bronchopulmonary neurons in the Guinea pig nucleus tractus solitarii","volume":"552","author":"Sekizawa","year":"2003","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2025.178312_bib127","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1038\/s41598-019-45014-4","article-title":"Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies","volume":"9","author":"Seretis","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178312_bib128","first-page":"14","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","author":"Shen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.178312_bib129","article-title":"Renin-angiotensin system blockade for the risk of cancer and death","volume":"17","author":"Shen","year":"2016","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS : JRAAS"},{"issue":"16_Suppl. l","key":"10.1016\/j.ejphar.2025.178312_bib130","article-title":"Impact of ACE inhibitors and ARBs on immunotherapy efficacy in advanced hepatocellular carcinoma","volume":"43","author":"Shi","year":"2025","journal-title":"ASCO Annual Meeting Abstracts"},{"key":"10.1016\/j.ejphar.2025.178312_bib131","doi-asserted-by":"crossref","first-page":"8854","DOI":"10.1038\/srep08854","article-title":"Pro)renin receptor is crucial for Wnt\/\u03b2-catenin-dependent genesis of pancreatic ductal adenocarcinoma","volume":"5","author":"Shibayama","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178312_bib132","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1527-5299.2002.01529.x","article-title":"Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy","volume":"8","author":"Sica","year":"2002","journal-title":"Congest. Heart Fail."},{"key":"10.1016\/j.ejphar.2025.178312_bib133","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/0886022X.2017.1361840","article-title":"Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney","volume":"39","author":"Simeoni","year":"2017","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ejphar.2025.178312_bib134","article-title":"[is it feasible to improve the duration and the efficiency of ramipril anti-proteinuric response?]","volume":"32","author":"Simeoni","year":"2015","journal-title":"G. Ital. Nefrol. : organo ufficiale della Societa italiana di nefrologia"},{"key":"10.1016\/j.ejphar.2025.178312_bib135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11255-015-1128-4","article-title":"Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis","volume":"48","author":"Simeoni","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.ejphar.2025.178312_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263461","article-title":"Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: meta-regression analysis of randomized trials","volume":"17","author":"Sipahi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178312_bib137","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2025.178312_bib138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/CLEP.S47150","article-title":"The impact of comorbidity on cancer survival: a review","volume":"5","author":"S\u00f8gaard","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ejphar.2025.178312_bib139","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178312_bib140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","article-title":"The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis","volume":"26","author":"Song","year":"2017","journal-title":"Eur. J. Cancer Prev. : the official journal of the European Cancer Prevention Organisation (ECP)"},{"key":"10.1016\/j.ejphar.2025.178312_bib141","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2174\/1381612033454171","article-title":"Bradykinin antagonists as anti-cancer agents","volume":"9","author":"Stewart","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2025.178312_bib142","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.3390\/ijms26188829","article-title":"Aldosterone: from essential tubular regulator to pathological driver\u2014physiology, disease, and therapeutic advances","volume":"26","author":"Strizzi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178312_bib143","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","article-title":"Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination","volume":"11","author":"Suganuma","year":"2005","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.ejphar.2025.178312_bib144","article-title":"Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: evidence from a meta-analysis including 55 studies","volume":"96","author":"Sun","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2025.178312_bib145","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2025.178312_bib146","article-title":"Prevalence of and survival with cachexia among patients with cancer: a systematic review and meta-analysis","volume":"15","author":"Takaoka","year":"2024","journal-title":"Advances in nutrition (Bethesda, Md"},{"key":"10.1016\/j.ejphar.2025.178312_bib147","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: Renin-angiotensin-aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178312_bib148","doi-asserted-by":"crossref","DOI":"10.1172\/JCI191934","article-title":"Cancer therapy and cachexia","volume":"135","author":"Thakir","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.178312_bib149","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1183\/09031936.93.06040576","article-title":"Kinins and respiratory tract diseases","volume":"6","author":"Trifilieff","year":"1993","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2025.178312_bib150","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1535-7163.MCT-04-0295","article-title":"Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells","volume":"4","author":"Uemura","year":"2005","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178312_bib151","first-page":"1139","article-title":"Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor","volume":"2","author":"Uemura","year":"2003","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178312_bib152","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Uresin","year":"2007","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS : JRAAS"},{"key":"10.1016\/j.ejphar.2025.178312_bib153","doi-asserted-by":"crossref","first-page":"35500","DOI":"10.18632\/oncotarget.26174","article-title":"Renin-angiotensin inhibitors reprogram tumor immune microenvironment: a comprehensive view of the influences on anti-tumor immunity","volume":"9","author":"Vallejo-Ardila","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178312_bib154","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000487","article-title":"Immunomodulatory effects of renin-angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases","volume":"8","author":"Vallejo Ardila","year":"2020","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.ejphar.2025.178312_bib155","first-page":"395","article-title":"Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?","volume":"95","author":"Vogt","year":"2004","journal-title":"Minerva Med."},{"key":"10.1016\/j.ejphar.2025.178312_bib156","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1172\/JCI118838","article-title":"Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats","volume":"98","author":"Volpert","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.178312_bib157","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.3892\/or.2016.5118","article-title":"Aliskiren targets multiple systems to alleviate cancer cachexia","volume":"36","author":"Wang","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejphar.2025.178312_bib158","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3892\/or.2014.3366","article-title":"Bradykinin stimulates IL-6 production and cell invasion in colorectal cancer cells","volume":"32","author":"Wang","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejphar.2025.178312_bib159","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12964-020-0531-3","article-title":"The (pro)renin receptor: a novel biomarker and potential therapeutic target for various cancers","volume":"18","author":"Wang","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejphar.2025.178312_bib160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41416-018-0350-0","article-title":"(Pro)renin receptor promotes colorectal cancer through the Wnt\/beta-catenin signalling pathway despite constitutive pathway component mutations","volume":"120","author":"Wang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178312_bib161","first-page":"2521","article-title":"Bradykinin promotes proliferation, migration, and invasion of cervical cancer cells through STAT3 signaling pathways","volume":"42","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejphar.2025.178312_bib163","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178312_bib164","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1751-7176.2011.00438.x","article-title":"Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients","volume":"13","author":"White","year":"2011","journal-title":"Journal of clinical hypertension (Greenwich, Conn.)"},{"key":"10.1016\/j.ejphar.2025.178312_bib165","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2025.178312_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.801228","article-title":"Dietary salt intake and gastric cancer risk: a systematic review and meta-analysis","volume":"8","author":"Wu","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.ejphar.2025.178312_bib167","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41416-022-02029-5","article-title":"Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis","volume":"128","author":"Wu","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178312_bib168","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3892\/ol.2024.14667","article-title":"Impact of ACEI\/ARB use on the survival of hypertensive patients with cancer: a meta-analysis","volume":"28","author":"Xiao","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejphar.2025.178312_bib169","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/0008-5472.CAN-24-0954","article-title":"ACE2 enhances sensitivity to PD-L1 blockade by inhibiting macrophage-induced immunosuppression and angiogenesis","volume":"85","author":"Xie","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178312_bib170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jcb.22383","article-title":"Bradykinin enhances cell migration in human chondrosarcoma cells through BK receptor signaling pathways","volume":"109","author":"Yang","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.178312_bib171","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1016-8478(23)13226-2","article-title":"Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF-Receptor pathway","volume":"20","author":"Yang","year":"2005","journal-title":"Mol. Cells"},{"key":"10.1016\/j.ejphar.2025.178312_bib172","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bcp.2013.10.016","article-title":"Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells","volume":"87","author":"Yu","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178312_bib173","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/jcp.24639","article-title":"Ang II-AT1R increases cell migration through PI3K\/AKT and NF-\u03baB pathways in breast cancer","volume":"229","author":"Zhao","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2025.178312_bib174","first-page":"131","article-title":"Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2","volume":"55","author":"Zhou","year":"2019","journal-title":"Int. J. Oncol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925010660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925010660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:35:19Z","timestamp":1766057719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925010660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":168,"alternative-id":["S0014299925010660"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178312","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of Aliskiren in cancer modulation compared to other Renin-Angiotensin inhibitors: an in-depth review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178312"}}